Australia markets close in 4 hours 29 minutes

GERN Dec 2024 5.500 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.9500+0.1000 (+11.76%)
As of 10:26AM EDT. Market open.
Full screen
Previous close0.8500
Open0.9500
Bid0.8000
Ask1.0500
Strike5.50
Expiry date2024-12-20
Day's range0.9500 - 0.9500
Contract rangeN/A
Volume2
Open interest116
  • Zacks

    Geron (GERN) Wins FDA Approval for Blood Cancer Drug, Stock Up

    Geron's (GERN) shares rise on approval of its first drug. The FDA approves imetelstat for the treatment of adult patients with lower-risk MDS with transfusion-dependent anemia.

  • Yahoo Finance Video

    Geron stock pops on FDA approval for blood cancer drug

    Shares of Geron (GERN) are trading higher Friday, propelled by the recent Food & Drug Administration (FDA) approval of the company's blood disorder drug, Rytelo. The treatment is for adults with low- to intermediate-1 risk of myelodysplastic syndromes, a type of cancer.  For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Angel Smith

  • Zacks

    Why Is Exact Sciences (EXAS) Down 17.5% Since Last Earnings Report?

    Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.